Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4251-4259

  Warm, Mathias ^a   Kates, R ^b   Grosse Onnebrink E M ^a   Stoff Khalili, M ^a   Hoopmann, M ^a   Mallmann, P ^a   Thomas, A ^c   Harbeck, N ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b REK Consulting   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Breast cancer; Cyclophosphamid; Docetaxel; Dose dense epirubicin; Pre operative therapy; Prediction of therapy response; Triple negative

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROGESTERONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GRANULOPOIESIS; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PREDICTION; PREOPERATIVE PERIOD; PRIMARY TUMOR; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS; YOUNG ADULT;

EID: 78650253330     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW and Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493, 1997.
2. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV and Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998.
3. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM and Bonichon F: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). Ann Oncol 10: 47-52, 1999.
4. Taucher S, Steger GG, Jakesz R, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H and Gnant M: Austrian Breast and Colorectal Cancer Study Group-07: The potential risk of neoadjuvant chemotherapy in breast cancer patients-results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07). Breast Cancer Res Treat 112: 309-316, 2008.
5. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez Lopez JJ, Mansutti M, Valagussa P and Bonadonna G: European Cooperative Trial in Operable Breast Cancer Study Group: Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11: 8715-8721, 2005.
6. Veronesi U, Bonadonna G, Zurrida S, Galimberti V, Greco M, Brambilla C, Luini A, Andreola S, Rilke F and Raselli R: Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 222: 612-618, 1995.
7. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL and Cronin WM: Re-analysis and results after 12 years of follow-up in a randomised clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 345: 1378-1387, 2001.
8. Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F and Konecny GE: Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 27: 2938-2945, 2009.
9. Mauriac L, Durand M, Avril A and Dilhuydy JM: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2: 347-354, 1991.
10. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangié T, Jouve M and Beuzeboc P: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645-652, 1994.
11. Wolmark N, Wang J, Mamounas E, Bryant J and Fisher B: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30: 96-102, 2001.
12. Warm M, Kates R, Mallmann P, Dick M, Nawroth F, Harbeck N, Paepke S and Thomas A: Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer. Antican Res 27: 1031-1038, 2007.
13. Untch M, Ditsch N and Bauerfeind I: Primäre Chemotherapie beim Mammakarzinom. In: Diagnostik und Therapie des Mammakarzinoms-State of the Art. W. Zuckerschwerdt, München, 2002.
14. von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M and German Breast Group: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophos-phamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100: 542-551, 2008.
15. Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A, Lindemann W, Jackisch C, Berdel WE, Kirchner H, Metzner B, Werner F, Schütt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S and West German Study Group: Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 19: 861-870, 2007.
16. Kobayashi S: Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer 15: 153-158, 2008.
17. Cheang MC, Voduc D and Bajdik C: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376, 2008.
18. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 227: 665-667, 1979.
19. Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M and von Minckwitz G: Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res: R69, 2009.
20. Estévez LG, Muñoz M, Alvarez I, Fernández Y, García-Mata J, Ruiz-Borrego M, Tusquets I, Seguí MA, Rodríguez-Lescure A, Adrover E and Lluch A: Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. Cancer Treat Rev 33: 474-483, 2007.
21. Early Breast Cancer Trialists' Collaborative Group: Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 1: CD000487, 2002.
22. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
23. Thomas A, Ohlinger R, Hauschild M, Mustea A, Blohmer JU and Kümmel S: Option and limit of surgery after preoperative chemotherapy in breast cancer. Antican Res 26: 1677-1682, 2006.
24. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG and Eremin O; Aberdeen Breast Group: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 3: S69-74, 2002.
25. von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, Jackisch C, du Bois A and Kaufmann M: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23: 2676-2685, 2005.
26. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K and von Minckwitz G: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28: 2024-2031, 2010.
27. Glueck S: The expanding role of epirubicin in the treatment of breast cancer. Cancer Control 9: 16-27, 2002.
28. Fumoleau P, Bonneterre J and Luporsi E: Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today? J Clin Oncol 21: 1190-1191, 2003.
29. Bedard PL, Di Leo A and Piccart-Gebhart MJ: Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 7: 22-36, 2010.
30. Nabholtz JM and Gligorov J: The role of taxanes in the treatment of breast cancer. Expert Opin Pharmacother 6: 1073-1094, 2005.
31. Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, García-Asenjo J, Guitián M, Almenar S, González-Palacios J, Vera F, Palacios J, Ramos M, Marco J, Lluch A, Alvarez I, Seguí M, Mayordomo J, Antón A, Baena J, Plazaola A, Modolell A, Pelegrí A, Mel J, Aranda E, Adrover E, Álvarez J, Puche J, Sánchez-Rovira P, Gonzalez S and López-Vega J: Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100: 805-814, 2008.
32. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A and Vogel C: Breast Cancer International Research Group 001 Investigators: 'Adjuvant docetaxel for node-positive breast cancer'. N Engl J Med 352: 2302-2313, 2005.
33. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB and Norton L: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431-1439, 2003.
34. Citron ML: Dose-dense chemotherapy for node-positive breast cancer. Ann Intern Med 142: 227, 2005.
35. Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE and Untch M: Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28: 2874-2880, 2010.
36. Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E and Hudis C: Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol 28: 2982-2988, 2010.
37. Gianni AM and Piccart MJ: Optimising chemotherapy dose density and dose intensity. New strategies to improve outcomes in adjuvant therapy for breast cancer. Eur J Cancer 36: S1-3, 2000.
38. Natoli C, Cianchetti E, Tinari N, Angelucci D, Grassadonia A, Zilli M, Ficorella C, Ricevuto E, Grossi S, De Tursi M, Carella C, Rispoli AI and Iacobelli S: A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. Ann Oncol 18: 1015-1020, 2007.
39. Rice GC, Ling V and Schimke RT: Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin) resistance. Proc Natl Acad Sci USA 84: 9261-9264, 1987.
40. Sanna K and Rofstad EK: Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer 15: 258-262, 1994.
41. Eiermann W, Bauerfeind I, Hanusch CA, Hasmüller S, Kahlert S, Kaiser C, Keim S, Mosner M, Oberlechner E, Paepke S, Raab G and Salat C: Primär systemische Therapie. In: Manual Mammakarzinome, Tumorzentrum München, 2009.
42. Cheung KL: Endocrine therapy for breast cancer: an overview. Breast 16: 327-343, 2007.
43. Paepke S, Jacobs VR, Paepke D, Euler U, Blohmer JU, Warm M, Ohlinger R, Fischer T, Kiechle M and Harbeck N: Critical appraisal of primary systemic endocrine therapy in receptor-positive postmenopausal breast cancer: an update. Onkologie 29: 210-217, 2006.
44. Petit T, Wilt M, Veiten M, Millon R, Rodier JF, Borel C, Mors R, Haegelé P, Eber M and Ghnassia JP: Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40: 205-211, 2004.
45. Bozzetti C, Musolino A, Camisa R, Bisagni G, Flora M, Bassano C, Martella E, Lagrasta C, Nizzoli R, Personeni N, Leonardi F, Cocconi G and Ardizzoni A: Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. Am J Clin Oncol 29: 171-177, 2006.
46. Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22, 2007.
47. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I and Coindre JM: Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74: 1458-1465, 1996.
48. Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, von Minckwitz G, Thomssen C and Harbeck N: uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 45: 31-45, 2008.
49. Olsson H, Baldetorp B, Ferno M and Perfekt R: Relation between the rate of tumour cell proliferation and latency time in radiation associated breast cancer. BMC Cancer 3: 11, 2003.
50. Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F, Veronesi P, Luini A, Orlando L, Viale G, Goldhirsch A and Colleoni M: Tailored preoperative treatment of locally advanced triple-negative (hormone receptor-negative and HER2-negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 62: 667-672, 2008.
51. http://www.germanbreastgroup.de/geparquinto